The Pharmaceutical Market: Hungary

Publication Date	September 2009
Publisher	Espicom
Product Type	Report
Pages	86
ISBN Number	not applicable
Product Code	ESP00002

Buy this product or for assistance call +44 20 7060 7474

PDF £595.00$990 | €666

PRINT £595.00$990 | €666

FAX Order above formats by FAX

Summary

Hungary represents one of the more advanced pharmaceutical markets of Central Europe. This report is ideal for executives wanting to understand the key drivers in the pharmaceutical market and have access to a wealth of statistical data, including five-year market projections. In addition to the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.

Includes 3 quarterly updated outlook reports!

Hungary is a landlocked country in central Europe. The population stands at 9.9 million in 2009, of whom 15.8% are aged 65 or over. Hungary is one of the ten countries that joined the EU in May 2004. EU Directives have been transposed into national legislation; Directive 2004/27/EC was implemented in November 2005.

Funding for healthcare in Hungary is managed by the National Health Insurance Fund Administration (NHIFA), which runs the only health insurance fund in the country. In February 2008, a new bill on health insurance was signed into law, which enabled private companies to buy shares in 22 new health funds. However, the legislation was repealed in May 2008 and the health funds are to be phased out.

Sources of funding for pharmaceuticals include the pharmaceutical industry itself as drug companies have been forced to contribute part of their turnover to the Health Insurance Fund, in order to cover government overspending. The Pharma Economic Act, which came into force in January 2007, successfully prevented the drugs budget from running into deficit for the first time in over a decade.

Manufacturers have reported loss of profits since the enforcement of the Pharma Economic Act. Reduced reimbursement rates and price cuts saw net profits of the leading domestic producer, Gedeon Richter, fall by 28.4% in 2007. Egis’ net income dropped by 50.6%. Tax implications and changes to the reimbursement system have discouraged investment in the country and have forced companies to look for opportunities elsewhere; Gedeon Richter is expanding its business in Poland and Russia, for instance.

In 2009, the Hungarian market for pharmaceuticals was estimated at US$3,189 million, equal to US$322 per capita. It is expected that the pharmaceutical market will continue to expand at a rate of 8.7% per annum, reaching US$4,846 million, or US$495 per capita by 2014.

Around 65% of the pharmaceutical market is supplied by imports. France, Germany and Switzerland were the leading suppliers in 2007, accounting for over 55% of imports. The value of imports has increased every year since 2001.

MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development

Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property

Pharmaceutical distribution

Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel

HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and healthcare personnel.

Content

EXECUTIVE SUMMARY

Introduction
Pharmaceutical Market Analysis
Size
Market Structure
    Generics Sector
    OTC Sector
Projections & Outlook
Imports
Domestic Manufacturing
Trade Associations
    AIPM
    MAGYOSZ
    Domestic Producers
    Biogal
    Chinoin
    Egis
    Gedeon Richter
    Human
    ICN Magyarorszag (Alkaloida)
    Keri Pharma
    Pharmavit
Exports
Research & Development
Pharmaceutical Regulatory Analysis
Pharmaceutical Regulation
    EU Regulatory Reforms
    Centralised procedure
    Mutual recognition procedure
    Pharmaceutical Registration
Advertising
Pricing & Reimbursement
    Decree 17/2007
    Price freezing and the Pharma Economic Act
Intellectual Property
Pharmaceutical Distribution
Wholesaling
    Distributors
    Hungaropharma
    Medimpex
    Pharmafontana
Retailing
Healthcare Analysis
Demographics
    Population
    Birth Rate
    Death Rate
    Infant Mortality
    Life Expectancy at Birth
    Public Health
    Causes of Death
    Incidence of Communicable Diseases
    Incidence of Non-communicable Diseases
    HIV/AIDS
Healthcare System
    National Health Fund Administration
    Local Government
    Private Healthcare
    Healthcare Reform
Health Expenditure
Healthcare Infrastructure
    Inpatient Analysis
Healthcare Personnel

DIRECTORY
Healthcare Organisations
Trade Associations
Methodology & Sources

List of Tables
    Summary of Key Data Projections, 2009-2014
    Summary of the Hungarian Pharmaceutical Market, 2009
    Per Capita Medicine Turnover by Area, 2006
    Market Projections, 2009-2014
    SWOT Analysis of the Hungarian Pharmaceutical Market, 2009
    Espicom Analysis of the Hungarian Health Sector, 2009
    Imports of Pharmaceuticals by Category, 2003-2007 (US$000s)
    Import Trends, 2006-2007 (US$000s)
    Leading Suppliers of Raw Materials, 2007 (US$000s)
    Leading Suppliers of Antisera & Vaccines, 2007 (US$000s)
    Leading Suppliers of Medicaments, 2007 (US$000s)
    Hungarian Pharmaceutical Production, 1990-2005 (HUF billions)
    Egis ANDA Approvals, 2002-2005
    Human Pharmaceuticals by Therapeutic Area, 2001-2005 (HUF millions)
    Leading Products by Turnover, 2007/8
    Egis Financial Results, 2002-2008 (HUF millions)
    Exports by Key Market, 2006-08 (US$000s)
    Gedeon Richter, Main Licensing Partners, 2008
    Product Sales by Therapeutic Group, 2002-2008 (%)
    Gedeon Richter, Top Ten Products, 2007-2008 (HUF millions)
    Gedeon Richter ANDA Approvals, 2002-2008
    Gedeon Richter Financial Results, 2001-2008 (HUF millions)
    Gedeon Richter, Top Ten Products in Hungary, 2007-2008 (HUF millions)
    Gedeon Richter Sales by Region, 2003-2008 (HUF millions)
    Gedeon Richter Top Ten Export Markets, 2007-2008 (US$ millions)
    Exports of Pharmaceuticals, 2003-2007 (US$000s)
    Export Trends, 2006-2007 (US$000s)
    Leading Destinations, 2007 (US$000s)
    Marketing Authorisation Fees, 2009
    Pharmacies, 1997-2006
    Summary of Demographic Data, 2006 & 2008
    Projected Population, 2009-2014
    Projected Health Expenditure, 2009-2014
    Hospitals & Beds, 2006
    Hospital Bed Projections, 2009-2014
    Projected Number of Physicians, 2009-2014

List of Charts
    Radar Graph of the Hungarian Healthcare System
    Gedeon Richter Products by Therapeutic Groups, 2008 (%)
    Gedeon Richter Key Markets Breakdown, 2008 (%)